Medtronic neurostimulation
This article was originally published in The Gray Sheet
Executive Summary
FDA approves Medtronic's Specify 5-6-5 surgical lead for treatment of chronic low back pain with its RestoreAdvanced and PrimeAdvanced neurostimulators, the company announces June 18. Specify 5-6-5 has 16 electrodes in three columns imbedded on a flexible paddle with proprietary DuraLoc technology. The curved shape of the paddle conforms to the epidural space around the spinal cord, allowing consistent contact of the electrodes with the spinal cord's surrounding membrane, Medtronic says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.